Shadi Yaghi1, Hooman Kamel1, Mitchell S V Elkind2. 1. From the Department of Neurology, College of Physicians and Surgeons (S.Y., M.S.V.E.), and Department of Epidemiology, Mailman School of Public Health (M.S.V.E.), Columbia University, New York; and Department of Neurology (H.K.), Weill Cornell Medical College, New York, NY. 2. From the Department of Neurology, College of Physicians and Surgeons (S.Y., M.S.V.E.), and Department of Epidemiology, Mailman School of Public Health (M.S.V.E.), Columbia University, New York; and Department of Neurology (H.K.), Weill Cornell Medical College, New York, NY. mse13@columbia.edu.
Abstract
BACKGROUND: Non-vitamin K antagonist oral anticoagulant (NOAC) drugs are at least equivalent to warfarin for ischemic stroke prevention in patients with atrial fibrillation and have a lower risk of intracranial hemorrhage. The role of these agents in the prevention and treatment of other types of cerebrovascular disease remains unclear. METHODS: We reviewed the literature (randomized trials, exploratory comparative studies, and case series) on the use of NOACs in patients with atrial fibrillation, venous thromboembolism, and cerebrovascular disease independent of atrial fibrillation. RESULTS: The literature on the use of NOACs for treatment and prevention of cerebrovascular disease in patients without atrial fibrillation is sparse. The potential benefit of vitamin K antagonists over antiplatelet agents for primary and secondary prevention in certain subsets of patients with cerebrovascular disease is offset by the increased risk of major and intracranial hemorrhage. Given that NOACs are equivalent to vitamin K antagonists in preventing ischemic stroke and systemic embolism in patients with atrial fibrillation with less bleeding risk, clinical trials are needed to investigate the short- and long-term use of NOACs in populations of patients with other forms of cerebrovascular disease, including those with cryptogenic stroke with or without evidence of patent foramen ovale and low ejection fraction, cervical artery dissection, large artery atherosclerosis, venous thrombosis, and stuttering lacunar stroke. CONCLUSION: There may be a role for NOACs in stroke prevention and treatment beyond atrial fibrillation. Randomized controlled trials are needed to compare NOACs to current stroke prevention and treatment strategies in certain subgroups of patients with cerebrovascular disease.
BACKGROUND: Non-vitamin K antagonist oral anticoagulant (NOAC) drugs are at least equivalent to warfarin for ischemic stroke prevention in patients with atrial fibrillation and have a lower risk of intracranial hemorrhage. The role of these agents in the prevention and treatment of other types of cerebrovascular disease remains unclear. METHODS: We reviewed the literature (randomized trials, exploratory comparative studies, and case series) on the use of NOACs in patients with atrial fibrillation, venous thromboembolism, and cerebrovascular disease independent of atrial fibrillation. RESULTS: The literature on the use of NOACs for treatment and prevention of cerebrovascular disease in patients without atrial fibrillation is sparse. The potential benefit of vitamin K antagonists over antiplatelet agents for primary and secondary prevention in certain subsets of patients with cerebrovascular disease is offset by the increased risk of major and intracranial hemorrhage. Given that NOACs are equivalent to vitamin K antagonists in preventing ischemic stroke and systemic embolism in patients with atrial fibrillation with less bleeding risk, clinical trials are needed to investigate the short- and long-term use of NOACs in populations of patients with other forms of cerebrovascular disease, including those with cryptogenic stroke with or without evidence of patent foramen ovale and low ejection fraction, cervical artery dissection, large artery atherosclerosis, venous thrombosis, and stuttering lacunar stroke. CONCLUSION: There may be a role for NOACs in stroke prevention and treatment beyond atrial fibrillation. Randomized controlled trials are needed to compare NOACs to current stroke prevention and treatment strategies in certain subgroups of patients with cerebrovascular disease.
Authors: Ralph L Sacco; Shyam Prabhakaran; J L P Thompson; Amy Murphy; Robert R Sciacca; Bruce Levin; J-P Mohr Journal: Cerebrovasc Dis Date: 2006-03-27 Impact factor: 2.762
Authors: I Meissner; J P Whisnant; B K Khandheria; P C Spittell; W M O'Fallon; R D Pascoe; M Enriquez-Sarano; J B Seward; J L Covalt; J D Sicks; D O Wiebers Journal: Mayo Clin Proc Date: 1999-09 Impact factor: 7.616
Authors: Steven C Cramer; Guy Rordorf; Jeffrey H Maki; Larry A Kramer; James C Grotta; W Scott Burgin; Judith A Hinchey; Curtis Benesch; Karen L Furie; Helmi L Lutsep; Ellen Kelly; W T Longstreth Journal: Stroke Date: 2003-12-04 Impact factor: 7.914
Authors: Cesare Russo; Zhezhen Jin; Rui Liu; Shinichi Iwata; Aylin Tugcu; Mitsuhiro Yoshita; Shunichi Homma; Mitchell S V Elkind; Tatjana Rundek; Charles Decarli; Clinton B Wright; Ralph L Sacco; Marco R Di Tullio Journal: JACC Cardiovasc Imaging Date: 2013-03
Authors: Patrick M Pullicino; Min Qian; Ralph L Sacco; Ron Freudenberger; Susan Graham; John R Teerlink; Douglas Mann; Marco R Di Tullio; Piotr Ponikowski; Dirk J Lok; Stefan D Anker; Gregory Y H Lip; Conrado J Estol; Bruce Levin; Jay P Mohr; John L P Thompson; Shunichi Homma Journal: Cerebrovasc Dis Date: 2014-10-09 Impact factor: 2.762
Authors: Robert G Hart; Hans-Christoph Diener; Shelagh B Coutts; J Donald Easton; Christopher B Granger; Martin J O'Donnell; Ralph L Sacco; Stuart J Connolly Journal: Lancet Neurol Date: 2014-04 Impact factor: 44.182
Authors: Robert P Giugliano; Christian T Ruff; Eugene Braunwald; Sabina A Murphy; Stephen D Wiviott; Jonathan L Halperin; Albert L Waldo; Michael D Ezekowitz; Jeffrey I Weitz; Jindřich Špinar; Witold Ruzyllo; Mikhail Ruda; Yukihiro Koretsune; Joshua Betcher; Minggao Shi; Laura T Grip; Shirali P Patel; Indravadan Patel; James J Hanyok; Michele Mercuri; Elliott M Antman Journal: N Engl J Med Date: 2013-11-19 Impact factor: 91.245
Authors: Santosh B Murthy; Ajay Gupta; Alexander E Merkler; Babak B Navi; Pitchaiah Mandava; Costantino Iadecola; Kevin N Sheth; Daniel F Hanley; Wendy C Ziai; Hooman Kamel Journal: Stroke Date: 2017-04-17 Impact factor: 7.914
Authors: Shyam Prabhakaran; Steven R Messé; Dawn Kleindorfer; Eric E Smith; Gregg C Fonarow; Haolin Xu; Xin Zhao; Barbara Lytle; Joaquin Cigarroa; Lee H Schwamm Journal: Neurol Clin Pract Date: 2020-10